10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2020-11-16 (Q3 2020) | Holdings: 120 | Value: $25.0B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| SGEN - Seagen Inc. | New Purchase | 36.96% | $9.3B | -10.39% | +3.71% | ||
| BGNE - BeiGene, Ltd. | Add 13% ($436.6M) | 15.22% | $3.8B | -11.54% | +28.78% | +36.93% | |
| INCY - Incyte Corporation | 11.47% | $2.9B | -22.41% | -0.10% | -22.46% | ||
| ACAD - ACADIA Pharmaceuticals Inc. | 6.91% | $1.7B | -60.18% | -7.57% | -64.04% | ||
| ALXN - Alexion Pharmaceuticals, Inc. | 4.01% | $1.0B | +22.84% | ||||
| KOD - Kodiak Sciences Inc. | Add 7% ($46.0M) | 2.92% | $731.4M | -96.84% | +28.45% | -5.02% | |
| BMRN - BioMarin Pharmaceutical Inc. | 2.31% | $577.4M | -24.81% | +11.10% | +4.54% | ||
| ASND - Ascendis Pharma A/S | Add 4% ($23.1M) | 2.18% | $546.3M | -0.91% | +2.34% | -5.71% | |
| NVTA - Invitae Corporation | 2.05% | $513.7M | +3.28% | -54.34% | |||
| MYOK - MyoKardia, Inc. | Reduce 5% $(21.1M) | 1.64% | $410.3M | ||||
| PRLD - Prelude Therapeutics Incorporated | New Purchase | 1.22% | $304.9M | -98.13% | +78.05% | -66.93% | |
| ARGX - argenx SE | 1.07% | $267.7M | +120.68% | +42.68% | +15.64% | ||
| MRTX - Mirati Therapeutics, Inc. | 0.94% | $234.1M | -10.05% | -37.58% | |||
| IGMS - IGM Biosciences, Inc. | 0.93% | $232.1M | -97.67% | +79.36% | +12.84% | ||
| EXAS - Exact Sciences Corporation | 0.75% | $188.2M | -53.17% | +17.33% | -26.45% | ||
| MDGL - Madrigal Pharmaceuticals, Inc. | 0.71% | $178.0M | +127.53% | +0.69% | -28.12% | ||
| AMRN - Amarin Corporation plc | Reduce 7% $(10.4M) | 0.54% | $134.8M | -87.48% | +68.47% | -10.80% | |
| HRTX - Heron Therapeutics, Inc. | 0.35% | $88.8M | -89.72% | +1.15% | -41.08% | ||
| FMTX - Forma Therapeutics Holdings, Inc. | Reduce 11% $(11.4M) | 0.35% | $88.3M | +4.93% | -54.64% | ||
| CERS - Cerus Corporation | 0.34% | $85.8M | -78.76% | +26.25% | +21.91% | ||
| ZYME - Zymeworks Inc. | 0.32% | $79.6M | -72.69% | -2.08% | -53.23% | ||
| INSM - Insmed Incorporated | Reduce 25% $(24.2M) | 0.29% | $73.0M | +91.46% | +17.08% | -16.67% | |
| AXSM - Axsome Therapeutics, Inc. | Reduce 5% $(3.6M) | 0.27% | $68.4M | +42.96% | -2.09% | -53.03% | |
| NBIX - Neurocrine Biosciences, Inc. | Reduce 25% $(22.1M) | 0.26% | $65.1M | +32.71% | +24.37% | -3.34% | |
| KYMR - Kymera Therapeutics, Inc. | New Purchase | 0.25% | $63.3M | -36.38% | +27.09% | +34.34% | |
| NRIX - Nurix Therapeutics, Inc. | New Purchase | 0.25% | $62.5M | -66.94% | +23.70% | +5.23% | |
| ALLK - Allakos Inc. | Reduce 5% $(3.0M) | 0.23% | $56.9M | +36.87% | -17.04% | ||
| ADCT - ADC Therapeutics SA | 0.22% | $55.7M | -90.87% | -6.76% | -26.17% | ||
| RYTM - Rhythm Pharmaceuticals, Inc. | Reduce 8% $(5.0M) | 0.21% | $53.5M | +181.33% | +31.79% | -44.95% | |
| HZNP - Horizon Therapeutics Public Ltd Co | New Purchase | 0.21% | $51.8M | +22.64% | +52.05% | ||
| GBT - Global Blood Therapeutics, Inc. | New Purchase | 0.20% | $50.7M | +16.10% | -22.15% | ||
| ADAP - Adaptimmune Therapeutics plc | Reduce 5% $(2.8M) | 0.20% | $50.5M | -94.18% | +31.61% | -15.90% | |
| BCEL - Atreca, Inc. | 0.20% | $49.4M | +23.96% | -65.35% | |||
| CCXI - ChemoCentryx, Inc. | Reduce 5% $(2.5M) | 0.20% | $49.3M | +4.55% | -32.97% | ||
| NLTX - Neoleukin Therapeutics, Inc. | Add 12% ($5.1M) | 0.18% | $45.9M | ||||
| BCRX - BioCryst Pharmaceuticals, Inc. | Reduce 8% $(3.7M) | 0.17% | $43.6M | +144.99% | +142.94% | +173.70% | |
| KNSA - Kiniksa Pharmaceuticals, Ltd. | 0.17% | $42.9M | +74.27% | +43.44% | -17.90% | ||
| N/A - Neurocrine Biosciences, Inc. | 0.17% | $42.3M | |||||
| KRYS - Krystal Biotech, Inc. | Reduce 5% $(1.8M) | 0.13% | $33.4M | +201.70% | +80.34% | +17.58% | |
| PACB - Pacific Biosciences of California, Inc. | New Purchase | 0.13% | $32.1M | -93.84% | +182.42% | +72.95% | |
| PTGX - Protagonist Therapeutics, Inc. | Reduce 16% $(6.2M) | 0.12% | $31.2M | +118.15% | +16.96% | +67.37% | |
| AGLE - Aeglea BioTherapeutics, Inc. | 0.12% | $31.1M | -93.68% | -23.99% | -29.89% | ||
| ALT - Altimmune, Inc. | Add 5% ($1.3M) | 0.12% | $29.1M | -41.99% | +159.72% | +14.96% | |
| APLS - Apellis Pharmaceuticals, Inc. | 0.11% | $27.0M | -55.83% | +19.57% | +17.71% | ||
| ASMB - Assembly Biosciences, Inc. | 0.10% | $25.3M | -78.83% | +9.34% | -55.30% | ||
| DBVT - DBV Technologies S.A. | 0.10% | $25.3M | -64.92% | +144.12% | +27.31% | ||
| MRUS - Merus N.V. | 0.10% | $24.4M | +319.37% | +76.06% | +113.39% | ||
| AUPH - Aurinia Pharmaceuticals Inc. | Reduce 5% $(1.2M) | 0.10% | $23.8M | -41.32% | +19.39% | +118.56% | |
| CBAY - Cymabay Therapeutics, Inc. | New Purchase | 0.09% | $23.5M | -31.27% | -49.05% | ||
| ALKS - Alkermes plc | Add 9% ($1.9M) | 0.09% | $22.5M | +72.92% | +11.01% | +28.68% | |
| ADPT - Adaptive Biotechnologies Corporation | Reduce 100% | 0.00% | $0.00 | -87.38% | +32.00% | -31.68% | |
| N/A - BioMarin Pharmaceutical Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| FREQ - Frequency Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| GWPH - GW Pharmaceuticals plc | Reduce 100% | 0.00% | $0.00 | ||||
| NVAX - Novavax, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| PRNB - Principia Biopharma Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| SGEN - Seattle Genetics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| TCDA - Tricida, Inc. | Reduce 100% | 0.00% | $0.00 | ||||